CiteAb - Data Accelerating Science Data Accelerating Science
Menu
  • Reagent Search
    • Antibodies
      Recombinant, monoclonal & polyclonal antibodies and primary & secondary antibodies.
    • Biochemicals
      Carbohydrates, peptides, bioactive small molecules, buffers, dyes and lipids.
    • Cell Lines & Models
      Cell lines, tissues, bacteria & viruses, and animal models.
    • Kits & Assays
      ELISAs, multiplex immunoassay kits, detection/staining kits and conjugation/labelling kits.
    • Instruments
      Microscopes, flow cytometers, spectrometers, and other laboratory instruments.
    • Nucleotides
      Plasmids, primers, RNA, siRNA, shRNA, gRNA, viral vectors and particles.
    • Proteins
      Enzymes, growth factors, binding proteins (e.g. streptavidin) and protein mixtures (e.g. bovine serum).
  • Image Search
  • Custom Suppliers
    • Antibody Suppliers
      Polyclonal, monoclonal, recombinant or alternative affinity reagent production.
    • Cell line Suppliers
      Knockout cell lines, knockin cell lines, gene activation & repression and reporter cell lines.
    • Histology Suppliers
      Immunohistochemistry (IHC), in situ hybridisation (ISH), tissue microarray staining (TMA), and more.
    • Peptides Suppliers
      Standard and modified sequences, fluorescent, isotope and radioactive labelled peptides, and more.
    • Sequencing Suppliers
      Whole Genome Sequencing, Antibody Sequencing, Targeted Sequencing, and more.
  • Supplier Partnerships
  • Data Services
    • Reagent Suppliers
      Powerful life science market data, accurate product citations & published images and listing on our popular reagent search engine.
    • Pharma, Biotech & Academic Research Institutions
      Accelerate preclinical research by licensing our comprehensive life science reagent database for totally flexible and private use.
    • Investment, Research & Advisory Companies
      Power unique and quantitative analysis into life science reagent and equipment manufacturer performance to help you make more informed investment decisions.
    • Scientific Publishers
      Partner with CiteAb to maximise exposure, researcher benefit and revenue from your publications.
  • Sign in or Register
Sign in or Register

Multi-path direct current spinal stimulation extended survival in the SOD1-G93A model of amyotrophic lateral sclerosis.

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons in the spinal cord and brain. We have developed a novel non-invasive approach, MultiPath-DCS, which utilizes direct current stimulation at multiple sites along the neural axis to provide simultaneous spinal and peripheral stimulation targeted at the affected limbs. MultiPath-DCS modulates the excitability of spinal cord neurons. This effect is significant for ALS, as motor neuron hyperexcitability is a fundamental characteristic of the disease.
This study used a transgenic mouse model of ALS (SOD1-G93A). Anodal-MultiPath-DCS was applied with six electrodes: three on the spine (centered on T13 and with an anodal polarity), two on the sciatic nerves (one on each nerve), and one on the abdomen. Mice were divided into two groups (stimulated vs. unstimulated or sham-stimulated). The stimulated animals received stimulation for one hour a day, three times a week, for three weeks. Survival was calculated from the onset of the disease and birth until the animal's endpoint. We also performed various electrophysiological and molecular experiments to uncover the mechanism of action.
We demonstrated molecular changes induced by anodal MultiPath-DCS, including (a) reduced expression of mutant SOD1 protein, (b) decreased expression of elevated NKCC1, (c) reduced phosphorylated tau, (d) increased expression of HSP70, and (e) increased expression of LC3B. Additionally, we found that treatment with Anodal-MultiPath-DCS (anode on the spinal column) reduces long-term neuronal spinal excitability, slows the progression of muscle weakness, and extends the lifespan of stimulated mice. The mean survival time in the control group was 12.4 days. In comparison, the mean survival time in the stimulated group was 21.6 days using a therapeutic stimulation paradigm, representing a 74% increase in survival from disease onset. Spinal motor neuron survival showed a 54% increase in stimulated compared to non-stimulated groups.
Combined, this data provides evidence that Anodal-MultiPath-DCS reduces hyperexcitability and enhances the clearance of misfolded proteins by modulating autophagy and proteolytic systems. By decreasing spinal excitability and clearing toxic proteins from motor neurons, Anodal-MultiPath-DCS promotes survival and could serve as a disease-modifying intervention for ALS.
Copyright © 2025 Ahmed, Samaddar, Hassieb, Sadek, Morozova and Begum.

Authors

Zaghloul Ahmed, Sreyashi Samaddar, May Hassieb, Rodina Sadek, Viktoriya Morozova, Sultana Begum

Center for Developmental Neuroscience, The College of Staten Island, City University of New York, Staten Island, NY, United States.

View Full Text PDF Article Galaxy PDF

Loading published images for this product

7 products referenced in this paper

(A-11001) Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488

an Antibody by Invitrogen Antibodies

Applications:

IHC and IHC-Fr-IF (1:500)

Tissue species:

Mus musculus (House mouse)

Images:

(AB144P) Anti-Choline Acetyltransferase Antibody

an Antibody by MM

Applications:

IHC (1:500)

Reactivity:

Mus musculus (House mouse)

(BA-9200) Goat Anti-Mouse IgG Antibody (H+L), Biotinylated

an Antibody by Vector Laboratories

Applications:

IHC (1:500)

Tissue species:

Mus musculus (House mouse)

4 more citations
Register a CiteAb account today to view them.
Sign in or Register now

Journal Frontiers in Neurology

Volume 16

Pages 1594169

Publication Date 11 July 2025

View on PubMed® View on Journal Website

Publication metadata is provided by PubMed®, courtesy of the U.S. National Library of Medicine. Information for this publication was last updated on 2026-08-11 16:27:13 UTC.

Join thousands of people who already enjoy the CiteAb newsletter

Stay up to date with improvements to the CiteAb Explore Platform and data services, news of our partnerships, product launches and the CiteAb Awards, and get our latest market data analysis straight to your inbox.

Sign up
×

We just need a few more details to better tailor our newsletter to you:

CiteAb Explore Platform
  • Image search engine
  • Antibody search engine
  • Biochemical search engine
  • Cell Lines & Models search engine
  • Kits & Assays search engine
  • Instruments search engine
  • Nucleotide search engine
  • Protein search engine
  • Custom suppliers
  • Request a Demo
Research Resources
  • Antibody dilution calculator
  • Molarity calculator
  • Finding the right antibody
  • Citing an antibody
Data Licensing
  • Pharma/Biotech
  • Finance
  • Publishers
  • Integrations
Market Data
  • Antibody market data
  • Biochemical market data
  • Cell Lines & Models market data
  • Instrument market data
  • Kits & Assay market data
  • Protein market data
Supplier Partnerships
  • Citation & Image Provision
  • Listing on CiteAb
  • Market Data
  • Case Studies
CiteAb Information
  • Our story
  • Blog
  • Contact
  • Careers
  • CiteAb publications
  • CiteAb awards
  • Facebook
  • LinkedIn
  • Instagram
The world's largest antibody search engine, with results ranked by citations.

Data Accelerating Science

CiteAb helps researchers find reliable reagents through the Explore Platform, combining powerful reagent and image search tools. We also license our world-class data to pharma & biotech companies, investors and sci-tech companies, and partner with leading life science suppliers.

Publication metadata is provided by PubMed®, a database of the US National Library of Medicine. PubMed® is a registered trademark of US National Library of Medicine.

Company registered in England #08530854. VAT #179706954.
Copyright © CiteAb Ltd 2026. All rights reserved.

  • Privacy policy
  • Cookie policy
  • Terms of use
  • Subscription Terms and Conditions

In partnership with:

  • Storm Consultancy
  • University of Bath
Proud recipient of the Queen's Award for Innovation 2022